Research Topics
- Lung Cancer
- Inflammation
- Targeted therapy
- Immunotherapy
Aktuelle Forschungsprojekte
Lung cancer is the most frequent cancer with an aggressive clinical course and high mortality rates. Most cases are diagnosed at advanced stages when treatment options are limited and the efficacy of chemotherapy is poor. The disease has a complex and heterogeneous background with non-small-cell lung cancer (NSCLC) accounting for 85% of patients and lung adenocarcinoma being the most common histological subtype. Almost 30% of lung adenocarcinomas are driven by an activating Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation. We are interested in developing therapeutic strategies tailored for KRAS driven NSCLC relying on the blockage of KRAS functional output, cellular dependencies, metabolic features and immunotherapy.
Selected Publications
- Caratti, B. et al., 2022. The glucocorticoid receptor associates with RAS complexes to inhibit cell proliferation and tumor growth. Science Signaling. Available at: https://www.science.org/doi/10.1126/scisignal.abm4452
- Breitenecker, K. et al., 2021. Downregulation of A20 promotes immune escape of lung adenocarcinomas. Science Translational Medicine.
Available at: https://doi.org/10.1126/scitranslmed.abc3911 - Mohrherr, J. et al., 2019. JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression. International Journal of Cancer.
Available at: https://doi.org/10.1002/ijc.32624 - Moll, H.P. et al., 2018. Afatinib restrains K-RAS-driven lung tumorigenesis. Science Translational Medicine.
Available at: http://dx.doi.org/10.1126/scitranslmed.aao2301 - Grabner, B. et al., 2015. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nature Communications.
Available at: http://dx.doi.org/10.1038/ncomms7285 - Musteanu, M. et al., 2012. A mouse model to identify cooperating signaling pathways in cancer. Nature Methods.
Available at: https://doi.org/10.1038/nmeth.2130